MGX participates in Isomorphic Labs’ $5B Series C funding round to accelerate AI-driven drug discovery
17 November 2026
MGX has made a follow-on investment in Isomorphic Labs, participating in its $5 billion Series C funding round alongside leading global investors. This investment reflects our continued conviction in the company’s vision and its potential to transform drug discovery through AI.
The funding will support the continued development of Isomorphic Labs’ proprietary AI drug design engine and accelerate its pipeline of AI-designed medicines, advancing the potential of artificial intelligence to deliver breakthrough treatments to patients.